Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Zacks Investment Research
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Continue Reading